

Correction: *Overcoming resistance to α PD-1 of MMR-deficient tumors with high tumor-induced neutrophils levels by combination of α CTLA-4 and α PD-1 blockers*

Nebot-Bral L, Hollebecque A, Yurchenko AA, *et al.* Overcoming resistance to α PD-1 of MMR-deficient tumors with high tumor-induced neutrophils levels by combination of α CTLA-4 and α PD-1 blockers. *J Immunother Cancer* 2022;10:e005059. doi: 10.1136/jitc-2022-005059

This article has been corrected since it was first published online. Patricia Kannouche has now been indicated as co-corresponding author.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See <http://creativecommons.org/licenses/by-nc/4.0/>.

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

J Immunother Cancer 2022;10:e005059corr1. doi:10.1136/jitc-2022-005059corr1

